title: Phase II/III randomized trial of TCH346 in patients with ALS.
abstract: BACKGROUND
  TCH346 exerts antiapoptotic effects by binding to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and blocking the apoptotic pathway in which GAPDH is involved. Apoptosis is considered to be a key pathogenic mechanism in neurodegenerative diseases including ALS.
  
  
  METHODS
  Patients were randomly assigned in a double-blind fashion to receive either placebo or one of four doses of TCH346 (1.0, 2.5, 7.5, or 15 mg/day) administered orally once daily for at least 24 weeks. The primary outcome measure was the rate of change in the revised ALS functional rating scale (ALSFRS-R). The trial design included a 16-week lead-in phase to determine each patient's rate of disease progression. The between treatment comparison was adjusted for the individual pretreatment rates of progression. The study was powered to detect a 25% reduction in the rate of decline of the ALSFRS-R as compared with placebo. Secondary outcome measures included survival, pulmonary function, and manual muscle testing (MMT).
  
  
  RESULTS
  Five hundred ninety-one patients were enrolled at 42 sites in Europe and North America. There were no differences in baseline variables. There were no significant differences between placebo and active treatment groups in the mean rate of decline of the ALSFRS-R or in the secondary outcome measures (survival, pulmonary function, and MMT).
  
  
  CONCLUSIONS
  The trial revealed no evidence of a beneficial effect of TCH346 on disease progression in patients with ALS.
authors: California Pacific Medical Center, San Francisco, CA 94115, USA. millerrx@sutterhealth.org
authors: R
authors: R
authors: Miller
authors: W
authors: W
authors: Bradley
authors: M
authors: M
authors: Cudkowicz
authors: J
authors: J
authors: Hubble
authors: V
authors: V
authors: Meininger
authors: H
authors: H
authors: Mitsumoto
authors: D
authors: D
authors: Moore
authors: H
authors: H
authors: Pohlmann
authors: D
authors: D
authors: Sauer
authors: V
authors: V
authors: Silani
authors: M
authors: M
authors: Strong
authors: M
authors: M
authors: Swash
authors: E
authors: E
authors: Vernotica
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D002490:Central Nervous System / Q000187:drug effects / Q000201:enzymology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000201:enzymology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects; D010082:Oxepins / Q000008:administration & dosage* / Q000009:adverse effects; D015990:Placebo Effect; D017211:Treatment Failure
chemical_list: D004791:Enzyme Inhibitors; D018696:Neuroprotective Agents; D010082:Oxepins; C111178:dibenzo(b,f)oxepin-10-ylmethyl-methyl-prop-2-ynyl-amine; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases